Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis

Takayuki Fujii, Ryo Yamasaki, Yukino Miyachi, Satoshi Nagata, Guzailiayi Maimaitijiang, Yuri Nakamura, Koji Shinoda, Takuya Matsushita, Noriko Isobe, Jun ichi Kira

Research output: Contribution to journalArticle

Abstract

Background: Nuclear antigen released from central nervous system (CNS) cells undergoing destruction may induce production of antinuclear antibodies (ANA). We characterized the CNS-specific production of ANA in multiple sclerosis (MS). Methods: We assessed CNS-ANA binding to mouse cerebellar cell nuclei by immunofluorescence assay (IFA) with sera from 104 MS patients (91 relapsing-remitting; 13 secondary progressive), 30 patients with neuromyelitis optica spectrum disorders (NMOSD), and 30 healthy controls (HCs). Conventional ANA (cANA) was detected by IFA using human epithelial type-2 cells. CNS-ANA-positive cANA-negative patients were termed CNS-specific ANA-positive. Western blotting (WB) was performed using mouse cerebellar nuclear fractions. Results: CNS-specific ANA were more frequent in MS than in NMOSD patients or HCs (13.5% vs 0% for both comparisons, both p < .05) and were associated with HLA-DRB1*15:01 (p = .0174). WB revealed a common 55 kDa band in seven MS patients. Compared with CNS-specific ANA-negative MS patients, those with 55 kDa band-immunoreactive CNS-specific ANA showed a higher frequency of secondary progressive MS (42.9% vs 10.0%, p = .0387) and greater Expanded Disability Status Scale scores (4.50 ± 2.02 vs 2.92 ± 2.27, p = .0506). Conclusions: The CNS-specific ANA was more frequently detected in MS patients than NMOSD patients or HCs. 55 kDa band-reactive CNS-specific ANA may reflect clinical disease progression in MS.

Original languageEnglish
Article number116619
JournalJournal of the Neurological Sciences
Volume409
DOIs
Publication statusPublished - Feb 15 2020

Fingerprint

Antinuclear Antibodies
Multiple Sclerosis
Central Nervous System
Neuromyelitis Optica
Fluorescent Antibody Technique
Western Blotting
Chronic Progressive Multiple Sclerosis
HLA-DRB1 Chains
Cerebellar Nuclei
Nuclear Antigens
Cell Nucleus
Disease Progression
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. / Fujii, Takayuki; Yamasaki, Ryo; Miyachi, Yukino; Nagata, Satoshi; Maimaitijiang, Guzailiayi; Nakamura, Yuri; Shinoda, Koji; Matsushita, Takuya; Isobe, Noriko; Kira, Jun ichi.

In: Journal of the Neurological Sciences, Vol. 409, 116619, 15.02.2020.

Research output: Contribution to journalArticle

Fujii, Takayuki ; Yamasaki, Ryo ; Miyachi, Yukino ; Nagata, Satoshi ; Maimaitijiang, Guzailiayi ; Nakamura, Yuri ; Shinoda, Koji ; Matsushita, Takuya ; Isobe, Noriko ; Kira, Jun ichi. / Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis. In: Journal of the Neurological Sciences. 2020 ; Vol. 409.
@article{a3e56cfba3364235b1dd3e6c5cade264,
title = "Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis",
abstract = "Background: Nuclear antigen released from central nervous system (CNS) cells undergoing destruction may induce production of antinuclear antibodies (ANA). We characterized the CNS-specific production of ANA in multiple sclerosis (MS). Methods: We assessed CNS-ANA binding to mouse cerebellar cell nuclei by immunofluorescence assay (IFA) with sera from 104 MS patients (91 relapsing-remitting; 13 secondary progressive), 30 patients with neuromyelitis optica spectrum disorders (NMOSD), and 30 healthy controls (HCs). Conventional ANA (cANA) was detected by IFA using human epithelial type-2 cells. CNS-ANA-positive cANA-negative patients were termed CNS-specific ANA-positive. Western blotting (WB) was performed using mouse cerebellar nuclear fractions. Results: CNS-specific ANA were more frequent in MS than in NMOSD patients or HCs (13.5{\%} vs 0{\%} for both comparisons, both p < .05) and were associated with HLA-DRB1*15:01 (p = .0174). WB revealed a common 55 kDa band in seven MS patients. Compared with CNS-specific ANA-negative MS patients, those with 55 kDa band-immunoreactive CNS-specific ANA showed a higher frequency of secondary progressive MS (42.9{\%} vs 10.0{\%}, p = .0387) and greater Expanded Disability Status Scale scores (4.50 ± 2.02 vs 2.92 ± 2.27, p = .0506). Conclusions: The CNS-specific ANA was more frequently detected in MS patients than NMOSD patients or HCs. 55 kDa band-reactive CNS-specific ANA may reflect clinical disease progression in MS.",
author = "Takayuki Fujii and Ryo Yamasaki and Yukino Miyachi and Satoshi Nagata and Guzailiayi Maimaitijiang and Yuri Nakamura and Koji Shinoda and Takuya Matsushita and Noriko Isobe and Kira, {Jun ichi}",
year = "2020",
month = "2",
day = "15",
doi = "10.1016/j.jns.2019.116619",
language = "English",
volume = "409",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis

AU - Fujii, Takayuki

AU - Yamasaki, Ryo

AU - Miyachi, Yukino

AU - Nagata, Satoshi

AU - Maimaitijiang, Guzailiayi

AU - Nakamura, Yuri

AU - Shinoda, Koji

AU - Matsushita, Takuya

AU - Isobe, Noriko

AU - Kira, Jun ichi

PY - 2020/2/15

Y1 - 2020/2/15

N2 - Background: Nuclear antigen released from central nervous system (CNS) cells undergoing destruction may induce production of antinuclear antibodies (ANA). We characterized the CNS-specific production of ANA in multiple sclerosis (MS). Methods: We assessed CNS-ANA binding to mouse cerebellar cell nuclei by immunofluorescence assay (IFA) with sera from 104 MS patients (91 relapsing-remitting; 13 secondary progressive), 30 patients with neuromyelitis optica spectrum disorders (NMOSD), and 30 healthy controls (HCs). Conventional ANA (cANA) was detected by IFA using human epithelial type-2 cells. CNS-ANA-positive cANA-negative patients were termed CNS-specific ANA-positive. Western blotting (WB) was performed using mouse cerebellar nuclear fractions. Results: CNS-specific ANA were more frequent in MS than in NMOSD patients or HCs (13.5% vs 0% for both comparisons, both p < .05) and were associated with HLA-DRB1*15:01 (p = .0174). WB revealed a common 55 kDa band in seven MS patients. Compared with CNS-specific ANA-negative MS patients, those with 55 kDa band-immunoreactive CNS-specific ANA showed a higher frequency of secondary progressive MS (42.9% vs 10.0%, p = .0387) and greater Expanded Disability Status Scale scores (4.50 ± 2.02 vs 2.92 ± 2.27, p = .0506). Conclusions: The CNS-specific ANA was more frequently detected in MS patients than NMOSD patients or HCs. 55 kDa band-reactive CNS-specific ANA may reflect clinical disease progression in MS.

AB - Background: Nuclear antigen released from central nervous system (CNS) cells undergoing destruction may induce production of antinuclear antibodies (ANA). We characterized the CNS-specific production of ANA in multiple sclerosis (MS). Methods: We assessed CNS-ANA binding to mouse cerebellar cell nuclei by immunofluorescence assay (IFA) with sera from 104 MS patients (91 relapsing-remitting; 13 secondary progressive), 30 patients with neuromyelitis optica spectrum disorders (NMOSD), and 30 healthy controls (HCs). Conventional ANA (cANA) was detected by IFA using human epithelial type-2 cells. CNS-ANA-positive cANA-negative patients were termed CNS-specific ANA-positive. Western blotting (WB) was performed using mouse cerebellar nuclear fractions. Results: CNS-specific ANA were more frequent in MS than in NMOSD patients or HCs (13.5% vs 0% for both comparisons, both p < .05) and were associated with HLA-DRB1*15:01 (p = .0174). WB revealed a common 55 kDa band in seven MS patients. Compared with CNS-specific ANA-negative MS patients, those with 55 kDa band-immunoreactive CNS-specific ANA showed a higher frequency of secondary progressive MS (42.9% vs 10.0%, p = .0387) and greater Expanded Disability Status Scale scores (4.50 ± 2.02 vs 2.92 ± 2.27, p = .0506). Conclusions: The CNS-specific ANA was more frequently detected in MS patients than NMOSD patients or HCs. 55 kDa band-reactive CNS-specific ANA may reflect clinical disease progression in MS.

UR - http://www.scopus.com/inward/record.url?scp=85075975066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075975066&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.116619

DO - 10.1016/j.jns.2019.116619

M3 - Article

C2 - 31835211

AN - SCOPUS:85075975066

VL - 409

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

M1 - 116619

ER -